04-09-01 A

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. B45096C1

First Named Inventor **Florent, et al.**

04/06/01 JC09 U.S. PTO

04/06/01 J1000 U.S. PTO 09/827785

"EXPRESS MAIL CERTIFICATE"

"EXPRESS MAIL" MAILING LABEL NUMBER EL737871132US DATE OF DEPOSIT: 06 April 2001

I hereby certify that this paper or fee and the papers indicated as being transmitted herewith are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date and with the Mailing Label Number indicated above and addressed to: The Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

NAME OF PERSON MAILING PAPER OR FEE (TYPE OR PRINT) Susan Dalm SIGNATURE

APPLICATION ELEMENTS *See MPEP chapter 600 concerning utility patent application contents.*	
1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. 19-2570 ☒ General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3)) *(Submit an original, and a duplicate for fee processing)*	7. ☒ The Title of the Invention: ACELLULAR PERTUSSIS VACCINE WITH DIPHTHERIA AND TETANUS-TOXOIDS
2. ☒ The total fee is calculated as shown below: Basic Filing fee $710.00 ☐ Total Claims 9 - 20 = 0 x $18 $ 0.00 ☐ Independent Claims 1 -3 = 0 x $80 $ 0.00 ☐ Multiple Dependent Claim present. $270 **TOTAL FILING FEE** **$710.00** ☐ Cancel in this application original claims _to __of the prior application before calculating the filing fee. ☒ **Charge $710.00** to the above indicated Deposit Account.	8. ☐ Nucleotide and/or Amino Acid Sequence Submission a. ☐ Computer Readable Copy b. ☐ Paper Copy (identical to computer copy) c. ☐ Statement verifying identity of above copies d. ☐ Use the identical computer-readable form filed in Application No. _____, filed ___ _ as the computer-readable form for the instant application. (37 CFR 1.821(e)) ACCOMPANYING APPLICATION PARTS 9. a. ☐ Information Disclosure Statement (IDS) b. ☐ PTO-1449 c. ☒ Copies of all IDS Citations 10. ☐ Assignment Papers (cover sheet & document(s))
	11. ☒ Prior Application is Assigned to: SmithKline Beecham Biologicals s.a. *(for continuation/divisional with Box 17a completed*
3a. ☒ Specification excluding Drawings [*Total Pages*] 11 3b. ☒ Abstract on a separate sheet [*Total Pages*] 1	12. ☒ Preliminary Amendment [*Total Pages*] 2
4. ☒ Drawing(s) (35 USC 113) [*Total Sheets*] 10	13. ☒ Return Receipt Postcard (MPEP 503) *(Should be specifically itemized)*
5. ☒ Declaration and Power of Attorney [*Total Pages*] 3 a. ☐ Newly executed (original or copy) b. ☒ Copy from a prior application (37 CFR 1.63(d)) *(for continuation/divisional with Box 17a completed)* c. ☐ Unsigned Declaration *[Note Box 6 below]* i. ☐ DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	14. ☐ Certified Copy of Priority Document(s) *(if foreign priority is claimed)* 15. ☒ Transfer all references cited by Applicants or by the Examiner from the parent Application Serial No. 09/284,887 filed May 27, 1999. A PTO-1449 listing the references is enclosed. 16. ☐ Other: _____
6. ☐ Incorporation By Reference *(useable if Box 5b is checked)* The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	

17.	☒ Priority Information, *check appropriate box and supply the requisite information*
a.	The accompanying application is a ☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: 09/284,887 filed May 27, 1999.
b.	☐ Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications: Application No. filed .
c.	☐ Please amend the specification by inserting before the first line the sentence: (37 CFR 1.78) This is a continuation/divisional of application Serial No. _____ filed _____.

18. CORRESPONDENCE ADDRESS			19. *RESPECTFULLY SUBMITTED,*	
Address	GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939		Signature Name	William R. Majarian
Telephone	(610) 270-5968	*Fax* (610) 270-5090	Registration No.	41,173

N:\Will\APPS\B45096\C1\153btrans.doc